BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 35878430)

  • 1. Design, synthesis and mechanistic studies of novel imidazo[1,2-a]pyridines as anticancer agents.
    Ismael AS; Amin NH; Elsaadi MT; Abdel-Rahman HM
    Bioorg Chem; 2022 Nov; 128():106042. PubMed ID: 35878430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, molecular docking, in silico ADMET profile and anticancer evaluations of sulfonamide endowed with hydrazone-coupled derivatives as VEGFR-2 inhibitors.
    Sayed AM; Taher FA; Abdel-Samad MRK; El-Gaby MSA; El-Adl K; Saleh NM
    Bioorg Chem; 2021 Mar; 108():104669. PubMed ID: 33515863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and molecular docking study of new pyrimidine-based hydrazones with selective anti-proliferative activity against MCF-7 and MDA-MB-231 human breast cancer cell lines.
    Badawi WA; Samir M; Fathy HM; Okda TM; Noureldin MH; Atwa GMK; AboulWafa OM
    Bioorg Chem; 2023 Sep; 138():106610. PubMed ID: 37210828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and molecular modeling studies of 2-styrylquinazoline derivatives as EGFR inhibitors and apoptosis inducers.
    Amin NH; Elsaadi MT; Zaki SS; Abdel-Rahman HM
    Bioorg Chem; 2020 Dec; 105():104358. PubMed ID: 33074119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel 1,3-diaryl pyrazole derivatives bearing methylsulfonyl moiety: Design, synthesis, molecular docking and dynamics, with dual activities as anti-inflammatory and anticancer agents through selectively targeting COX-2.
    Shaker AMM; Shahin MI; AboulMagd AM; Abdel Aleem SA; Abdel-Rahman HM; Abou El Ella DA
    Bioorg Chem; 2022 Dec; 129():106143. PubMed ID: 36191430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, molecular docking and anti-proliferative evaluations of [1,2,4]triazolo[4,3-a]quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors.
    El-Adl K; El-Helby AA; Sakr H; Elwan A
    Bioorg Chem; 2020 Dec; 105():104399. PubMed ID: 33113414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and bioevaluation and doking study of 1H-pyrrolo[2,3-b]pyridine derivatives bearing aromatic hydrazone moiety as c-Met inhibitors.
    Wang W; Xu S; Duan Y; Liu X; Li X; Wang C; Zhao B; Zheng P; Zhu W
    Eur J Med Chem; 2018 Feb; 145():315-327. PubMed ID: 29331754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of some new 6-bromo-2-(pyridin-3-yl)-4-substituted quinazolines as multi tyrosine kinase inhibitors.
    Farouk AKBAW; Abdelrasheed Allam H; Rashwan E; George RF; Abbas SE
    Bioorg Chem; 2022 Nov; 128():106099. PubMed ID: 35994884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel benzotriazole N-acylarylhydrazone hybrids: Design, synthesis, anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis and FAK inhibition.
    Kassab AE; Hassan RA
    Bioorg Chem; 2018 Oct; 80():531-544. PubMed ID: 30014921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, modeling studies and biological evaluation of pyrazole derivatives linked to oxime and nitrate moieties as nitric oxide donor selective COX-2 and aromatase inhibitors with dual anti-inflammatory and anti-neoplastic activities.
    A A Fadaly W; A M M Elshaier Y; T M Nemr M; R A Abdellatif K
    Bioorg Chem; 2023 May; 134():106428. PubMed ID: 36893546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, in vitro anticancer activity and in silico studies of certain pyrazole-based derivatives as potential inhibitors of cyclin dependent kinases (CDKs).
    Mohammed EZ; Mahmoud WR; George RF; Hassan GS; Omar FA; Georgey HH
    Bioorg Chem; 2021 Nov; 116():105347. PubMed ID: 34555628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel 1,2,4-triazole derivatives as potential anticancer agents: Design, synthesis, molecular docking and mechanistic studies.
    El-Sherief HAM; Youssif BGM; Bukhari SNA; Abdel-Aziz M; Abdel-Rahman HM
    Bioorg Chem; 2018 Feb; 76():314-325. PubMed ID: 29227915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
    Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
    Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, Synthesis and Antiproliferative Evaluation of Novel 1,2,4-Triazole/Schiff Base Hybrids with EGFR and B-RAF Inhibitory Activities.
    El-Sherief HAM; Youssif BGM; Abdelazeem AH; Abdel-Aziz M; Abdel-Rahman HM
    Anticancer Agents Med Chem; 2019; 19(5):697-706. PubMed ID: 30582484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and SARs study of novel spiro-oxindoles as potent antiproliferative agents with CDK-2 inhibitory activities.
    Al-Jassas RM; Islam MS; Al-Majid AM; Nafie MS; Haukka M; Rahman AFMM; Alayyaf AMA; Barakat A
    Arch Pharm (Weinheim); 2023 Aug; 356(8):e2300185. PubMed ID: 37253118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
    Maher M; Kassab AE; Zaher AF; Mahmoud Z
    Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, In Vitro Evaluation and Molecular Docking Studies of Novel Thiophenyl Thiazolyl-Pyridine Hybrids as Potential Anticancer Agents.
    Ashmawy FO; Gomha SM; Abdallah MA; Zaki MEA; Al-Hussain SA; El-Desouky MA
    Molecules; 2023 May; 28(11):. PubMed ID: 37298747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of certain aminoquinazoline scaffolds as potential multitarget anticancer agents with apoptotic and anti-proliferative effects: Design, synthesis and biological evaluation.
    Amin NH; El-Saadi MT; Abdel-Fattah MM; Mohammed AA; Said EG
    Bioorg Chem; 2023 Jun; 135():106496. PubMed ID: 36989735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-Substituted-4-phenylphthalazin-1-amine-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluation studies.
    El-Adl K; Ibrahim MK; Khedr F; Abulkhair HS; Eissa IH
    Arch Pharm (Weinheim); 2021 Mar; 354(3):e2000219. PubMed ID: 33197080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel triazolophthalazine-hydrazone hybrids as potential PCAF inhibitors: Design, synthesis, in vitro anticancer evaluation, apoptosis, and molecular docking studies.
    Abulkhair HS; Turky A; Ghiaty A; Ahmed HEA; Bayoumi AH
    Bioorg Chem; 2020 Jul; 100():103899. PubMed ID: 32454390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.